Takeda

Linkedin

“The U.S. FDA has approved our subcutaneous immunoglobulin therapy containing immunoglobulin and hyaluronidase as a maintenance treatment option for adults with chronic inflammatory demyelinating polyneuropathy (#CIDP).


Learn more: https://bit.ly/48U9y6B